

Risk of severe COVID-19 outcomes associated with immunosuppressive and immune modifying therapies: a nationwide cohort study

DOI: [10.1101/2021.09.03.21262888](https://doi.org/10.1101/2021.09.03.21262888)

Citation Report

#	ARTICLE	IF	CITATIONS
2	A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report. Wellcome Open Research, 0, 6, 360.	0.9	8
3	Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. Gut, 2023, 72, 410-412.	6.1	5
4	Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2022, 71, 1426-1439.	6.1	20